<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01311661</url>
  </required_header>
  <id_info>
    <org_study_id>1222.29</org_study_id>
    <secondary_id>2008-006625-14</secondary_id>
    <nct_id>NCT01311661</nct_id>
  </id_info>
  <brief_title>A Study to Compare the Efficacy and Safety of Different Dosings of Olodaterol Administered With the Respimat® Inhaler in Patients With Moderate to Severe Asthma</brief_title>
  <official_title>Phase II, Randomised, Double-Blind, Cross-over Study to Compare the 24-hour FEV1-time Profile of Orally Inhaled Olodaterol, Delivered With the Respimat® Inhaler, After 3 Weeks of Olodaterol Once Daily Medium Dose, Twice Daily Low Dose and Placebo or After 3 Weeks of Once Daily High Dose, Twice Daily Medium Dose and Placebo Administration in Patients With Moderate to Severe Persistent Asthma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      This study will compare efficacy and safety of different regimens of olodaterol
      administration in asthma (once daily, twice daily) with placebo in a complete cross-over
      design each within one of the two daily dose groups (medium or high daily dose).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2011</start_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Forced Expiratory Volume in 1 Second (FEV1) Area Under Curve 0-24 Hours (AUC 0-24h) Response at the End of Each Treatment Period</measure>
    <time_frame>1 hour (h) prior and 10 minutes (min) prior to first dose (baseline) and -1 h, -10 mins, 30 min, 60 min, 2 h, 3 h, 4 h, 6 h, 8 h, 10 h, 11 h 50 min, 12 h 30 min, 13 h, 14 h, 22 h, 23 h, and 23 h 50 min related to morning dose after 3 weeks</time_frame>
    <description>Response was defined as change from baseline. Study baseline FEV1 was defined as the mean of the available pre-dose FEV1 values at the randomisation visit. Means are adjusted for treatment, period, patient and study baseline. FEV1 AUC 0-24h was calculated from 0-24 hours post-dose using the trapezoidal rule, divided by the observation time (24h) to report in litres.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>FEV1 Area Under Curve 0-12 Hours (AUC 0-12h) Response at the End of Each Treatment Period</measure>
    <time_frame>1 hour (h) prior and 10 minutes (min) prior to first dose (baseline) and -1 h, -10 mins, 30 min, 60 min, 2 h, 3 h, 4 h, 6 h, 8 h, 10 h, 11 h 50 min related to morning dose after 3 weeks</time_frame>
    <description>Response was defined as change from baseline. Study baseline FEV1 was defined as the mean of the available pre-dose FEV1 values at the randomisation visit. Means are adjusted for treatment, period, patient and study baseline. FEV1 AUC 0-12h was calculated from 0-12 hours post-dose using the trapezoidal rule, divided by the observation time (12h) to report in litres.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FEV1 Area Under Curve 12-24 Hours (AUC 12-24h) Response at the End of Each Treatment Period</measure>
    <time_frame>1 hour (h) prior and 10 minutes (min) prior to first dose (baseline) and 11 h 50 min, 12 h 30 min, 13 h, 14 h, 22 h, 23 h, and 23 h 50 min related to morning dose after 3 weeks</time_frame>
    <description>Response was defined as change from baseline. Study baseline FEV1 was defined as the mean of the available pre-dose FEV1 values at the randomisation visit. Means are adjusted for treatment, period, patient and study baseline. FEV1 AUC 12-24h was calculated from 12-24 hours post-dose using the trapezoidal rule, divided by the observation time (12h) to report in litres.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak FEV1 Within 24 Hours Post-dose Response</measure>
    <time_frame>1 hour (h) prior and 10 minutes (min) prior to first dose (baseline) and 30 min, 60 min, 2 h, 3 h, 4 h, 6 h, 8h, 10 h, 11 h 50 min, 12 h 30 min, 13 h, 14 h, 22 h, 23 h, and 23 h 50 min related to morning dose after 3 weeks</time_frame>
    <description>Response was defined as change from baseline. Study baseline FEV1 was defined as the mean of the available pre-dose FEV1 values at the randomisation visit. Peak FEV1 within 24 hours post dose measured following the morning trial drug inhalation at the end of each 3 week period of randomised treatment. Means are adjusted for treatment, period, patient and study baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough FEV1 Response</measure>
    <time_frame>1 hour (h) prior and 10 minutes (min) prior to first dose (baseline) and 23 h, and 23 h 50 min related to morning dose after 3 weeks</time_frame>
    <description>Response was defined as change from baseline. Study baseline FEV1 was defined as the mean of the available pre-dose FEV1 values at the randomisation visit. Trough values were defined as the mean of 2 FEV1 values performed at 23 h and 23 h 50 min after the last morning trial drug inhalation at the end of each 3 week period of randomised treatment. Means are adjusted for treatment, period, patient and study baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Forced Vital Capacity (FVC) Area Under Curve 0-12 Hours (AUC 0-12h) Response</measure>
    <time_frame>1 hour (h) prior and 10 minutes (min) prior to first dose (baseline) and -1 h, -10 mins, 30 min, 60 min, 2 h, 3 h, 4 h, 6 h, 8 h, 10 h, 11 h 50 min related to morning dose after 3 weeks</time_frame>
    <description>Response was defined as change from baseline. Study baseline FVC was defined as the mean of the available pre-dose FVC values at the randomisation visit. Means are adjusted for treatment, period, patient and study baseline. FVC AUC 0-12h was calculated using the trapezoidal rule, divided by the observation time to report in litres.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FVC Area Under Curve 12-24 Hours (AUC 12-24h) Response</measure>
    <time_frame>1 hour (h) prior and 10 minutes (min) prior to first dose (baseline) and 11 h 50 min, 12 h 30 min, 13 h, 14 h, 22 h, 23 h, and 23 h 50 min related to morning dose after 3 weeks</time_frame>
    <description>Response was defined as change from baseline. Study baseline FVC was defined as the mean of the available pre-dose FVC values at the randomisation visit. Means are adjusted for treatment, period, patient and study baseline. FVC AUC 12-24h was calculated using the trapezoidal rule, divided by the observation time to report in litres.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FVC Area Under Curve 0-24 Hours (AUC 0-24h) Response</measure>
    <time_frame>1 hour (h) prior and 10 minutes (min) prior to first dose (baseline) and -1 h, -10 mins, 30 min, 60 min, 2 h, 3 h, 4 h, 6 h, 8h, 10 h, 11 h 50 min, 12 h 30 min, 13 h, 14 h, 22 h, 23 h, and 23 h 50 min related to morning dose after 3 weeks</time_frame>
    <description>Response was defined as change from baseline. Study baseline FVC was defined as the mean of the available pre-dose FVC values at the randomisation visit. Means are adjusted for treatment, period, patient and study baseline. FVC AUC 0-24h was calculated using the trapezoidal rule, divided by the observation time to report in litres.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak FVC Within 24 Hours Post-dose Response</measure>
    <time_frame>1 hour (h) prior and 10 minutes (min) prior to first dose (baseline) and 30 min, 60 min, 2 h, 3 h, 4 h, 6 h, 8h, 10 h, 11 h 50 min, 12 h 30 min, 13 h, 14 h, 22 h, 23 h, and 23 h 50 min related to morning dose after 3 weeks</time_frame>
    <description>Response was defined as change from baseline. Study baseline FVC was defined as the mean of the available pre-dose FVC values at the randomisation visit. Peak FVC within 24 hours post-dose measured following the morning trial drug inhalation at the end of each 3 week period of randomised treatment. Means are adjusted for treatment, period, patient and study baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough FVC Response</measure>
    <time_frame>1 hour (h) prior and 10 minutes (min) prior to first dose (baseline) and 23 h, and 23 h 50 min related to morning dose after 3 weeks</time_frame>
    <description>Response was defined as change from baseline. Study baseline FVC was defined as the mean of the available pre-dose FVC values at the randomisation visit. Trough values were defined as the mean of 2 FVC values performed at 23 h and 23 h 50 min after the last morning trial drug inhalation at the end of each 3 week period of randomised treatment. Means are adjusted for treatment, period, patient and study baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak Expiratory Flow (PEF) Area Under Curve 0-12 Hours (AUC 0-12h) Response</measure>
    <time_frame>1 hour (h) prior and 10 minutes (min) prior to first dose (baseline) and -1 h, -10 mins, 30 min, 60 min, 2 h, 3 h, 4 h, 6 h, 8h, 10 h, 11 h 50 min related to morning dose after 3 weeks</time_frame>
    <description>Response was defined as change from baseline. Study baseline PEF was defined as the mean of the available pre-dose PEF values at the randomisation visit. Means are adjusted for treatment, period, patient and study baseline. PEF AUC 0-12h was calculated using the trapezoidal rule, divided by the observation time to report in litres/seconds.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PEF Area Under Curve 12-24 Hours (AUC 12-24h) Response</measure>
    <time_frame>1 hour (h) prior and 10 minutes (min) prior to first dose (baseline) and 11 h 50 min, 12 h 30 min, 13 h, 14 h, 22 h, 23 h, and 23 h 50 min related to morning dose after 3 weeks</time_frame>
    <description>Response was defined as change from baseline. Study baseline PEF was defined as the mean of the available pre-dose PEF values at the randomisation visit. Means are adjusted for treatment, period, patient and study baseline. PEF AUC 12-24h was calculated using the trapezoidal rule, divided by the observation time to report in litres/seconds.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak Expiratory Flow (PEF) Area Under Curve 0-24 Hours (AUC 0-24h) Response</measure>
    <time_frame>1 hour (h) prior and 10 minutes (min) prior to first dose (baseline) and -1 h, -10 mins, 30 min, 60 min, 2 h, 3 h, 4 h, 6 h, 8h, 10 h, 11 h 50 min, 12 h 30 min, 13 h, 14 h, 22 h, 23 h, and 23 h 50 min related to morning dose after 3 weeks</time_frame>
    <description>Response was defined as change from baseline. Study baseline PEF was defined as the mean of the available pre-dose PEF values at the randomisation visit. Means are adjusted for treatment, period, patient and study baseline. PEF AUC 0-24h was calculated using the trapezoidal rule, divided by the observation time to report in litres/seconds.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak PEF Within 24 Hours Post-dose Response</measure>
    <time_frame>1 hour (h) prior and 10 minutes (min) prior to first dose (baseline) and 30 min, 60 min, 2 h, 3 h, 4 h, 6 h, 8h, 10 h, 11 h 50 min, 12 h 30 min, 13 h, 14 h, 22 h, 23 h, and 23 h 50 min related to morning dose after 3 weeks</time_frame>
    <description>Response was defined as change from baseline. Study baseline PEF was defined as the mean of the available pre-dose PEF values at the randomisation visit. Peak PEF within 24 hours post dose measured following the morning trial drug inhalation at the end of each 3 week period of randomised treatment. Means are adjusted for treatment, period, patient and study baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough PEF Response</measure>
    <time_frame>1 hour (h) prior and 10 minutes (min) prior to first dose (baseline) and 23 h, and 23 h 50 min related to morning dose after 3 weeks</time_frame>
    <description>Response was defined as change from baseline. Study baseline PEF was defined as the mean of the available pre-dose PEF values at the randomisation visit. Trough values were defined as the mean of 2 PEF values performed at 23 h and 23 h 50 min after the last morning trial drug inhalation at the end of each 3 week period of randomised treatment. Means are adjusted for treatment, period, patient and study baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Pre-dose Morning PEF (PEF a.m.)</measure>
    <time_frame>0-3 weeks</time_frame>
    <description>PEF a.m. was measured by patients at home using the AM3 device (overall means obtained during each period of randomised treatment will be compared). Means are adjusted for treatment, period, patient and study baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Pre-dose Evening PEF (PEF p.m.)</measure>
    <time_frame>0-3 weeks</time_frame>
    <description>PEF p.m. was measured by patients at home using the AM3 device (overall means obtained during each period of randomised treatment will be compared). Means are adjusted for treatment, period, patient and study baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PEF Daily Variability</measure>
    <time_frame>0-3 weeks</time_frame>
    <description>PEF daily variability was assessed by patients at home using the AM3 device (overall means obtained during each period of randomised treatment will be compared). PEF daily variability is the absolute difference between the morning and the evening PEF value divided by the mean of these two values, expressed as a percent. Means are adjusted for treatment, period, patient and study baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Pre-dose Morning FEV1 (FEV1 a.m.)</measure>
    <time_frame>0-3 weeks</time_frame>
    <description>FEV1 a.m. was measured by patients at home using the AM3 device (overall means obtained during each period of randomised treatment will be compared). Means are adjusted for treatment, period, patient and study baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Pre-dose Evening FEV1 (FEV1 p.m.)</measure>
    <time_frame>0-3 weeks</time_frame>
    <description>FEV1 p.m. was measured by patients at home using the AM3 device (overall means obtained during each period of randomised treatment will be compared). Means are adjusted for treatment, period, patient and study baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Number of Puffs of Rescue Medication During the Whole Day</measure>
    <time_frame>0-3 weeks</time_frame>
    <description>Mean of daily use of salbutamol (albuterol) rescue medication as needed during the entire study period. Assessed by patients at home using the AM3 device (overall mean number obtained during each period of randomised treatment will be compared). Means are adjusted for treatment, period, patient and study baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Asthma Symptom Free Days</measure>
    <time_frame>0-3 weeks</time_frame>
    <description>Percentage of asthma-symptom free days of each treatment period was calculated as the number of symptom-free days divided by the number of days on treatment multiplied by 100. A symptom-free day was defined as a day in which no asthma symptoms were recorded, no rescue medication was recorded, activities during the day were not at all limited due to asthma, no shortness of breath during the day was recorded, no wheezing or coughing during the day and no night-time awakenings due to asthma were recorded. Assessed by patients at home using the AM3 device.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients Categorized by Highest Number of Night Time Awakenings (Overall)</measure>
    <time_frame>0-3 weeks</time_frame>
    <description>Assessed by patients at home using the AM3 device during each period of randomised treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients Categorized by Worst Asthma Daytime Symptoms (Overall)</measure>
    <time_frame>0-3 weeks</time_frame>
    <description>Assessed by patients at home using the AM3 device during each period of randomised treatment .</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients Categorized by Worst Asthma Nighttime Symptoms (Overall)</measure>
    <time_frame>0-3 weeks</time_frame>
    <description>Assessed by patients at home using the AM3 device during each period of randomised treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Asthma Control Questionnaire (ACQ) Score</measure>
    <time_frame>3 weeks</time_frame>
    <description>Control of asthma as assessed by the ACQ at the end of each 3-week treatment period.The ACQ contains 7 questions, each question has a 7 point scale from 0 (no symptoms) till 6 (highest intensity). Total score was defined as the sum of all items divided by the number of items.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Relevant Abnormalities for Vital Signs, Blood Chemistry, Haematology, Urinalysis and ECG</measure>
    <time_frame>3 weeks + 12 days</time_frame>
    <description>Clinical relevant abnormalities for Vital Signs, Blood Chemistry, Haematology, Urinalysis and ECG. New abnormal findings or worsening of baseline conditions were reported as Adverse Events. Time frame for adverse event reporting includes 12 days into the subsequent washout or post-treatment period.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">206</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>Olodaterol medium daily dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Olodaterol medium daily dose given either as once daily or split into two low doses daily or placebo only in randomised sequence of three cross-over treatment phases</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Olodaterol high daily dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Olodaterol high daily dose given either as once daily or split into two medium doses daily or placebo only in randomised sequence of three cross-over treatment phases</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo twice daily</intervention_name>
    <description>Inhaled Placebo of Olodaterol twice daily</description>
    <arm_group_label>Olodaterol high daily dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Olodaterol low daily dose twice daily</intervention_name>
    <description>Inhaled Olodaterol medium daily dose administered as low dose twice daily</description>
    <arm_group_label>Olodaterol medium daily dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Olodaterol medium daily dose twice daily</intervention_name>
    <description>Inhaled Olodaterol high daily dose administered as medium dose twice daily</description>
    <arm_group_label>Olodaterol high daily dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo twice daily</intervention_name>
    <description>Inhaled Placebo of Olodaterol twice daily</description>
    <arm_group_label>Olodaterol medium daily dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Olodaterol high daily dose once daily and placebo</intervention_name>
    <description>Inhaled Olodaterol high daily dose administered as one full dose once daily and placebo once daily</description>
    <arm_group_label>Olodaterol high daily dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Olodaterol medium daily dose once daily and placebo</intervention_name>
    <description>Inhaled Olodaterol medium daily dose administered as one full dose once daily and placebo once daily</description>
    <arm_group_label>Olodaterol medium daily dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. Patients of either sex.

          2. Aged 18 to 70 years.

          3. A current diagnosis and a documented minimum 3 month history of asthma Global
             Initiative for Asthma (GINA) treatment steps 3 and 4.

          4. Prebronchodilator Forced Expiratory Volume in one second (FEV1) &gt;= 60% predicted and &lt;
             90% predicted according to European Coal and Steel Community (ECSC).

          5. Increase in FEV1 &gt;=12% and &gt;=200 mL 15 min. after 400 µg salbutamol (albuterol);

          6. Stable on medium to high dose inhaled corticosteroids (ICS) or low to high dose ICS in
             combination with a long acting beta-adrenergics (LABA) for at least 6 weeks prior to
             screening. Stable on ICS mono component of the former fixed LABA/ICS treatment for at
             least 48 hours prior to Visit 1b.

        Exclusion criteria:

          1. Patients with a significant disease other than asthma.

          2. History of frequent seasonal exacerbations of asthma (defined as one or more seasonal
             exacerbations every year for the past three years).

          3. Upper respiratory tract infection in the past 3 weeks prior to screening visit 1b.

          4. Oral or other systemic corticosteroids in the past 6 weeks.

          5. Patients with allergen desensitization therapy if started within two years, if they
             are not on an established maintenance regimen characterized by dose adjustments but no
             further increase to the tolerable maximum in the same course of immunotherapy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>1222.29.11006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Huntington Beach</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.29.11001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Centennial</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.29.11012 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Wheat Ridge</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.29.11002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.29.11004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>North Dartmouth</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.29.11011 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.29.11009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Skillman</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.29.11003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.29.11008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Canton</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.29.11007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.29.11005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Spartanburg</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.29.11010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.29.43003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Linz</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.29.43002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Schlüsslberg</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.29.43001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Thalheim bei Wels</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.29.43004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Wels</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.29.49004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.29.49006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.29.49007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.29.49008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.29.49002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Frankfurt</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.29.49010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Großhansdorf</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.29.49003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lübeck</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.29.49005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Rüdersdorf</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.29.49001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Wiesbaden</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.29.49009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Wiesloch</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.29.36002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Mosonmagyarovar</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.29.36003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nyiregyhaza</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.29.36001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sopron</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.29.36004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Zalaegerszeg</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.29.42001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bardejov</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.29.42002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Martin</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.29.42004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nitra</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.29.42003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Spisska Nova Ves</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.29.38003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Golnik</city>
        <country>Slovenia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.29.38002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kamnik</city>
        <country>Slovenia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Slovakia</country>
    <country>Slovenia</country>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 4, 2011</study_first_submitted>
  <study_first_submitted_qc>March 8, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 9, 2011</study_first_posted>
  <results_first_submitted>March 28, 2014</results_first_submitted>
  <results_first_submitted_qc>March 28, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 1, 2014</results_first_posted>
  <last_update_submitted>March 28, 2014</last_update_submitted>
  <last_update_submitted_qc>March 28, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 1, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Olodaterol</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Study Total</title>
          <description>This was a double-blind, 3-period crossover trial. 206 patients were assigned randomly to one of 12 treatment sequences with either 5 microgram (mcg) Olodaterol (Olo) once daily (qd) and 2.5 mcg Olodaterol twice daily (bid) and placebo (6 sequences) or 10 mcg Olodaterol qd and 5 mcg Olodaterol bid and placebo (6 sequences). The duration of each treatment period was 3 weeks separated by washout periods of 2 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="206">Entered and treated</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Placebo</title>
              <participants_list>
                <participants group_id="P1" count="201"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Olo 2.5 mcg Bid</title>
              <participants_list>
                <participants group_id="P1" count="101"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Olo 5 mcg qd</title>
              <participants_list>
                <participants group_id="P1" count="101"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Olo 5 mcg Bid</title>
              <participants_list>
                <participants group_id="P1" count="101"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Olo 10 mcg qd</title>
              <participants_list>
                <participants group_id="P1" count="102"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="199"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Study Total</title>
          <description>This was a double-blind, 3-period crossover trial. 206 patients were assigned randomly to one of 12 treatment sequences with either 5 microgram (mcg) Olodaterol (Olo) once daily (qd) and 2.5 mcg Olodaterol twice daily (bid) and placebo (6 sequences) or 10 mcg Olodaterol qd and 5 mcg Olodaterol bid and placebo (6 sequences). The duration of each treatment period was 3 weeks separated by washout periods of 2 weeks.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="206"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43.7" spread="12.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Number of participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="109"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Forced Expiratory Volume in 1 Second (FEV1) Area Under Curve 0-24 Hours (AUC 0-24h) Response at the End of Each Treatment Period</title>
        <description>Response was defined as change from baseline. Study baseline FEV1 was defined as the mean of the available pre-dose FEV1 values at the randomisation visit. Means are adjusted for treatment, period, patient and study baseline. FEV1 AUC 0-24h was calculated from 0-24 hours post-dose using the trapezoidal rule, divided by the observation time (24h) to report in litres.</description>
        <time_frame>1 hour (h) prior and 10 minutes (min) prior to first dose (baseline) and -1 h, -10 mins, 30 min, 60 min, 2 h, 3 h, 4 h, 6 h, 8 h, 10 h, 11 h 50 min, 12 h 30 min, 13 h, 14 h, 22 h, 23 h, and 23 h 50 min related to morning dose after 3 weeks</time_frame>
        <population>Full analysis set (FAS). FAS is defined as all patients in the treated set for whom the baseline (pre-dose) value is available, and who have a value for the primary endpoint for at least one crossover period.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo delivered by the Respimat Inhaler. Two actuations bid (morning and evening dosing).</description>
          </group>
          <group group_id="O2">
            <title>Olo 2.5 mcg Bid</title>
            <description>Olodaterol 2.5 mcg bid delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olo 5 mcg qd</title>
            <description>Olodaterol 5 mcg qd (morning) and matching Placebo in the evening delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O4">
            <title>Olo 5 mcg Bid</title>
            <description>Olodaterol 5 mcg bid delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O5">
            <title>Olo 10 mcg qd</title>
            <description>Olodaterol 10 mcg qd (morning) and matching Placebo in the evening delivered by the Respimat Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>Forced Expiratory Volume in 1 Second (FEV1) Area Under Curve 0-24 Hours (AUC 0-24h) Response at the End of Each Treatment Period</title>
          <description>Response was defined as change from baseline. Study baseline FEV1 was defined as the mean of the available pre-dose FEV1 values at the randomisation visit. Means are adjusted for treatment, period, patient and study baseline. FEV1 AUC 0-24h was calculated from 0-24 hours post-dose using the trapezoidal rule, divided by the observation time (24h) to report in litres.</description>
          <population>Full analysis set (FAS). FAS is defined as all patients in the treated set for whom the baseline (pre-dose) value is available, and who have a value for the primary endpoint for at least one crossover period.</population>
          <units>Liter</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="200"/>
                <count group_id="O2" value="99"/>
                <count group_id="O3" value="99"/>
                <count group_id="O4" value="100"/>
                <count group_id="O5" value="101"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.022" spread="0.020"/>
                    <measurement group_id="O2" value="0.213" spread="0.024"/>
                    <measurement group_id="O3" value="0.173" spread="0.024"/>
                    <measurement group_id="O4" value="0.250" spread="0.024"/>
                    <measurement group_id="O5" value="0.231" spread="0.024"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.191</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.020</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.152</ci_lower_limit>
            <ci_upper_limit>0.229</ci_upper_limit>
            <estimate_desc>Olo 2.5 mcg bid minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.150</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.020</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.111</ci_lower_limit>
            <ci_upper_limit>0.189</ci_upper_limit>
            <estimate_desc>Olo 5 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.228</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.020</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.190</ci_lower_limit>
            <ci_upper_limit>0.266</ci_upper_limit>
            <estimate_desc>Olo 5 mcg bid minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.209</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.020</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.170</ci_lower_limit>
            <ci_upper_limit>0.247</ci_upper_limit>
            <estimate_desc>Olo 10 mcg qd minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FEV1 Area Under Curve 0-12 Hours (AUC 0-12h) Response at the End of Each Treatment Period</title>
        <description>Response was defined as change from baseline. Study baseline FEV1 was defined as the mean of the available pre-dose FEV1 values at the randomisation visit. Means are adjusted for treatment, period, patient and study baseline. FEV1 AUC 0-12h was calculated from 0-12 hours post-dose using the trapezoidal rule, divided by the observation time (12h) to report in litres.</description>
        <time_frame>1 hour (h) prior and 10 minutes (min) prior to first dose (baseline) and -1 h, -10 mins, 30 min, 60 min, 2 h, 3 h, 4 h, 6 h, 8 h, 10 h, 11 h 50 min related to morning dose after 3 weeks</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo delivered by the Respimat Inhaler. Two actuations bid (morning and evening dosing).</description>
          </group>
          <group group_id="O2">
            <title>Olo 2.5 mcg Bid</title>
            <description>Olodaterol 2.5 mcg bid delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olo 5 mcg qd</title>
            <description>Olodaterol 5 mcg qd (morning) and matching Placebo in the evening delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O4">
            <title>Olo 5 mcg Bid</title>
            <description>Olodaterol 5 mcg bid delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O5">
            <title>Olo 10 mcg qd</title>
            <description>Olodaterol 10 mcg qd (morning) and matching Placebo in the evening delivered by the Respimat Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>FEV1 Area Under Curve 0-12 Hours (AUC 0-12h) Response at the End of Each Treatment Period</title>
          <description>Response was defined as change from baseline. Study baseline FEV1 was defined as the mean of the available pre-dose FEV1 values at the randomisation visit. Means are adjusted for treatment, period, patient and study baseline. FEV1 AUC 0-12h was calculated from 0-12 hours post-dose using the trapezoidal rule, divided by the observation time (12h) to report in litres.</description>
          <population>FAS</population>
          <units>Liter</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="200"/>
                <count group_id="O2" value="99"/>
                <count group_id="O3" value="99"/>
                <count group_id="O4" value="100"/>
                <count group_id="O5" value="101"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.052" spread="0.020"/>
                    <measurement group_id="O2" value="0.242" spread="0.024"/>
                    <measurement group_id="O3" value="0.212" spread="0.024"/>
                    <measurement group_id="O4" value="0.266" spread="0.024"/>
                    <measurement group_id="O5" value="0.272" spread="0.024"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.190</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.020</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.150</ci_lower_limit>
            <ci_upper_limit>0.229</ci_upper_limit>
            <estimate_desc>Olo 2.5 mcg bid minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.160</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.020</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.121</ci_lower_limit>
            <ci_upper_limit>0.199</ci_upper_limit>
            <estimate_desc>Olo 5 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.214</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.020</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.175</ci_lower_limit>
            <ci_upper_limit>0.253</ci_upper_limit>
            <estimate_desc>Olo 5 mcg bid minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.219</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.020</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.181</ci_lower_limit>
            <ci_upper_limit>0.258</ci_upper_limit>
            <estimate_desc>Olo 10 mcg qd minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FEV1 Area Under Curve 12-24 Hours (AUC 12-24h) Response at the End of Each Treatment Period</title>
        <description>Response was defined as change from baseline. Study baseline FEV1 was defined as the mean of the available pre-dose FEV1 values at the randomisation visit. Means are adjusted for treatment, period, patient and study baseline. FEV1 AUC 12-24h was calculated from 12-24 hours post-dose using the trapezoidal rule, divided by the observation time (12h) to report in litres.</description>
        <time_frame>1 hour (h) prior and 10 minutes (min) prior to first dose (baseline) and 11 h 50 min, 12 h 30 min, 13 h, 14 h, 22 h, 23 h, and 23 h 50 min related to morning dose after 3 weeks</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo delivered by the Respimat Inhaler. Two actuations bid (morning and evening dosing).</description>
          </group>
          <group group_id="O2">
            <title>Olo 2.5 mcg Bid</title>
            <description>Olodaterol 2.5 mcg bid delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olo 5 mcg qd</title>
            <description>Olodaterol 5 mcg qd (morning) and matching Placebo in the evening delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O4">
            <title>Olo 5 mcg Bid</title>
            <description>Olodaterol 5 mcg bid delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O5">
            <title>Olo 10 mcg qd</title>
            <description>Olodaterol 10 mcg qd (morning) and matching Placebo in the evening delivered by the Respimat Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>FEV1 Area Under Curve 12-24 Hours (AUC 12-24h) Response at the End of Each Treatment Period</title>
          <description>Response was defined as change from baseline. Study baseline FEV1 was defined as the mean of the available pre-dose FEV1 values at the randomisation visit. Means are adjusted for treatment, period, patient and study baseline. FEV1 AUC 12-24h was calculated from 12-24 hours post-dose using the trapezoidal rule, divided by the observation time (12h) to report in litres.</description>
          <population>FAS</population>
          <units>Liter</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="201"/>
                <count group_id="O2" value="99"/>
                <count group_id="O3" value="99"/>
                <count group_id="O4" value="100"/>
                <count group_id="O5" value="101"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.010" spread="0.020"/>
                    <measurement group_id="O2" value="0.186" spread="0.025"/>
                    <measurement group_id="O3" value="0.135" spread="0.025"/>
                    <measurement group_id="O4" value="0.233" spread="0.025"/>
                    <measurement group_id="O5" value="0.189" spread="0.025"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.196</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.022</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.153</ci_lower_limit>
            <ci_upper_limit>0.238</ci_upper_limit>
            <estimate_desc>Olo 2.5 mcg bid minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.144</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.022</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.102</ci_lower_limit>
            <ci_upper_limit>0.187</ci_upper_limit>
            <estimate_desc>Olo 5 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.242</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.022</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.200</ci_lower_limit>
            <ci_upper_limit>0.285</ci_upper_limit>
            <estimate_desc>Olo 5 mcg bid minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.198</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.022</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.156</ci_lower_limit>
            <ci_upper_limit>0.241</ci_upper_limit>
            <estimate_desc>Olo 10 mcg qd minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Peak FEV1 Within 24 Hours Post-dose Response</title>
        <description>Response was defined as change from baseline. Study baseline FEV1 was defined as the mean of the available pre-dose FEV1 values at the randomisation visit. Peak FEV1 within 24 hours post dose measured following the morning trial drug inhalation at the end of each 3 week period of randomised treatment. Means are adjusted for treatment, period, patient and study baseline.</description>
        <time_frame>1 hour (h) prior and 10 minutes (min) prior to first dose (baseline) and 30 min, 60 min, 2 h, 3 h, 4 h, 6 h, 8h, 10 h, 11 h 50 min, 12 h 30 min, 13 h, 14 h, 22 h, 23 h, and 23 h 50 min related to morning dose after 3 weeks</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo delivered by the Respimat Inhaler. Two actuations bid (morning and evening dosing).</description>
          </group>
          <group group_id="O2">
            <title>Olo 2.5 mcg Bid</title>
            <description>Olodaterol 2.5 mcg bid delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olo 5 mcg qd</title>
            <description>Olodaterol 5 mcg qd (morning) and matching Placebo in the evening delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O4">
            <title>Olo 5 mcg Bid</title>
            <description>Olodaterol 5 mcg bid delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O5">
            <title>Olo 10 mcg qd</title>
            <description>Olodaterol 10 mcg qd (morning) and matching Placebo in the evening delivered by the Respimat Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>Peak FEV1 Within 24 Hours Post-dose Response</title>
          <description>Response was defined as change from baseline. Study baseline FEV1 was defined as the mean of the available pre-dose FEV1 values at the randomisation visit. Peak FEV1 within 24 hours post dose measured following the morning trial drug inhalation at the end of each 3 week period of randomised treatment. Means are adjusted for treatment, period, patient and study baseline.</description>
          <population>FAS</population>
          <units>Liter</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="201"/>
                <count group_id="O2" value="99"/>
                <count group_id="O3" value="99"/>
                <count group_id="O4" value="100"/>
                <count group_id="O5" value="101"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.227" spread="0.021"/>
                    <measurement group_id="O2" value="0.410" spread="0.027"/>
                    <measurement group_id="O3" value="0.380" spread="0.027"/>
                    <measurement group_id="O4" value="0.449" spread="0.027"/>
                    <measurement group_id="O5" value="0.437" spread="0.026"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.183</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.023</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.138</ci_lower_limit>
            <ci_upper_limit>0.228</ci_upper_limit>
            <estimate_desc>Olo 2.5 mcg bid minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.153</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.023</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.108</ci_lower_limit>
            <ci_upper_limit>0.198</ci_upper_limit>
            <estimate_desc>Olo 5 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.222</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.023</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.177</ci_lower_limit>
            <ci_upper_limit>0.267</ci_upper_limit>
            <estimate_desc>Olo 5 mcg bid minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.210</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.023</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.165</ci_lower_limit>
            <ci_upper_limit>0.255</ci_upper_limit>
            <estimate_desc>Olo 10 mcg qd minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Trough FEV1 Response</title>
        <description>Response was defined as change from baseline. Study baseline FEV1 was defined as the mean of the available pre-dose FEV1 values at the randomisation visit. Trough values were defined as the mean of 2 FEV1 values performed at 23 h and 23 h 50 min after the last morning trial drug inhalation at the end of each 3 week period of randomised treatment. Means are adjusted for treatment, period, patient and study baseline.</description>
        <time_frame>1 hour (h) prior and 10 minutes (min) prior to first dose (baseline) and 23 h, and 23 h 50 min related to morning dose after 3 weeks</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo delivered by the Respimat Inhaler. Two actuations bid (morning and evening dosing).</description>
          </group>
          <group group_id="O2">
            <title>Olo 2.5 mcg Bid</title>
            <description>Olodaterol 2.5 mcg bid delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olo 5 mcg qd</title>
            <description>Olodaterol 5 mcg qd (morning) and matching Placebo in the evening delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O4">
            <title>Olo 5 mcg Bid</title>
            <description>Olodaterol 5 mcg bid delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O5">
            <title>Olo 10 mcg qd</title>
            <description>Olodaterol 10 mcg qd (morning) and matching Placebo in the evening delivered by the Respimat Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>Trough FEV1 Response</title>
          <description>Response was defined as change from baseline. Study baseline FEV1 was defined as the mean of the available pre-dose FEV1 values at the randomisation visit. Trough values were defined as the mean of 2 FEV1 values performed at 23 h and 23 h 50 min after the last morning trial drug inhalation at the end of each 3 week period of randomised treatment. Means are adjusted for treatment, period, patient and study baseline.</description>
          <population>FAS</population>
          <units>Liter</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="201"/>
                <count group_id="O2" value="99"/>
                <count group_id="O3" value="99"/>
                <count group_id="O4" value="100"/>
                <count group_id="O5" value="101"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.033" spread="0.022"/>
                    <measurement group_id="O2" value="0.189" spread="0.027"/>
                    <measurement group_id="O3" value="0.134" spread="0.027"/>
                    <measurement group_id="O4" value="0.229" spread="0.027"/>
                    <measurement group_id="O5" value="0.205" spread="0.027"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.156</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.024</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.109</ci_lower_limit>
            <ci_upper_limit>0.203</ci_upper_limit>
            <estimate_desc>Olo 2.5 mcg bid minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.101</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.024</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.054</ci_lower_limit>
            <ci_upper_limit>0.148</ci_upper_limit>
            <estimate_desc>Olo 5 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.196</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.024</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.149</ci_lower_limit>
            <ci_upper_limit>0.243</ci_upper_limit>
            <estimate_desc>Olo 5 mcg bid minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.172</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.024</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.125</ci_lower_limit>
            <ci_upper_limit>0.219</ci_upper_limit>
            <estimate_desc>Olo 10 mcg qd minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Forced Vital Capacity (FVC) Area Under Curve 0-12 Hours (AUC 0-12h) Response</title>
        <description>Response was defined as change from baseline. Study baseline FVC was defined as the mean of the available pre-dose FVC values at the randomisation visit. Means are adjusted for treatment, period, patient and study baseline. FVC AUC 0-12h was calculated using the trapezoidal rule, divided by the observation time to report in litres.</description>
        <time_frame>1 hour (h) prior and 10 minutes (min) prior to first dose (baseline) and -1 h, -10 mins, 30 min, 60 min, 2 h, 3 h, 4 h, 6 h, 8 h, 10 h, 11 h 50 min related to morning dose after 3 weeks</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo delivered by the Respimat Inhaler. Two actuations bid (morning and evening dosing).</description>
          </group>
          <group group_id="O2">
            <title>Olo 2.5 mcg Bid</title>
            <description>Olodaterol 2.5 mcg bid delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olo 5 mcg qd</title>
            <description>Olodaterol 5 mcg qd (morning) and matching Placebo in the evening delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O4">
            <title>Olo 5 mcg Bid</title>
            <description>Olodaterol 5 mcg bid delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O5">
            <title>Olo 10 mcg qd</title>
            <description>Olodaterol 10 mcg qd (morning) and matching Placebo in the evening delivered by the Respimat Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>Forced Vital Capacity (FVC) Area Under Curve 0-12 Hours (AUC 0-12h) Response</title>
          <description>Response was defined as change from baseline. Study baseline FVC was defined as the mean of the available pre-dose FVC values at the randomisation visit. Means are adjusted for treatment, period, patient and study baseline. FVC AUC 0-12h was calculated using the trapezoidal rule, divided by the observation time to report in litres.</description>
          <population>FAS</population>
          <units>Liter</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="200"/>
                <count group_id="O2" value="99"/>
                <count group_id="O3" value="99"/>
                <count group_id="O4" value="100"/>
                <count group_id="O5" value="101"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.004" spread="0.022"/>
                    <measurement group_id="O2" value="0.132" spread="0.027"/>
                    <measurement group_id="O3" value="0.119" spread="0.027"/>
                    <measurement group_id="O4" value="0.138" spread="0.026"/>
                    <measurement group_id="O5" value="0.143" spread="0.026"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.136</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.023</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.091</ci_lower_limit>
            <ci_upper_limit>0.180</ci_upper_limit>
            <estimate_desc>Olo 2.5 mcg bid minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.122</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.023</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.078</ci_lower_limit>
            <ci_upper_limit>0.167</ci_upper_limit>
            <estimate_desc>Olo 5 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.142</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.022</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.098</ci_lower_limit>
            <ci_upper_limit>0.186</ci_upper_limit>
            <estimate_desc>Olo 5 mcg bid minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.147</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.022</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.103</ci_lower_limit>
            <ci_upper_limit>0.191</ci_upper_limit>
            <estimate_desc>Olo 10 mcg qd minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FVC Area Under Curve 12-24 Hours (AUC 12-24h) Response</title>
        <description>Response was defined as change from baseline. Study baseline FVC was defined as the mean of the available pre-dose FVC values at the randomisation visit. Means are adjusted for treatment, period, patient and study baseline. FVC AUC 12-24h was calculated using the trapezoidal rule, divided by the observation time to report in litres.</description>
        <time_frame>1 hour (h) prior and 10 minutes (min) prior to first dose (baseline) and 11 h 50 min, 12 h 30 min, 13 h, 14 h, 22 h, 23 h, and 23 h 50 min related to morning dose after 3 weeks</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo delivered by the Respimat Inhaler. Two actuations bid (morning and evening dosing).</description>
          </group>
          <group group_id="O2">
            <title>Olo 2.5 mcg Bid</title>
            <description>Olodaterol 2.5 mcg bid delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olo 5 mcg qd</title>
            <description>Olodaterol 5 mcg qd (morning) and matching Placebo in the evening delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O4">
            <title>Olo 5 mcg Bid</title>
            <description>Olodaterol 5 mcg bid delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O5">
            <title>Olo 10 mcg qd</title>
            <description>Olodaterol 10 mcg qd (morning) and matching Placebo in the evening delivered by the Respimat Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>FVC Area Under Curve 12-24 Hours (AUC 12-24h) Response</title>
          <description>Response was defined as change from baseline. Study baseline FVC was defined as the mean of the available pre-dose FVC values at the randomisation visit. Means are adjusted for treatment, period, patient and study baseline. FVC AUC 12-24h was calculated using the trapezoidal rule, divided by the observation time to report in litres.</description>
          <population>FAS</population>
          <units>Liter</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="201"/>
                <count group_id="O2" value="99"/>
                <count group_id="O3" value="99"/>
                <count group_id="O4" value="100"/>
                <count group_id="O5" value="101"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.056" spread="0.023"/>
                    <measurement group_id="O2" value="0.102" spread="0.028"/>
                    <measurement group_id="O3" value="0.081" spread="0.028"/>
                    <measurement group_id="O4" value="0.114" spread="0.028"/>
                    <measurement group_id="O5" value="0.079" spread="0.028"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.158</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.024</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.110</ci_lower_limit>
            <ci_upper_limit>0.206</ci_upper_limit>
            <estimate_desc>Olo 2.5 mcg bid minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.137</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.024</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.090</ci_lower_limit>
            <ci_upper_limit>0.185</ci_upper_limit>
            <estimate_desc>Olo 5 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.170</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.024</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.123</ci_lower_limit>
            <ci_upper_limit>0.218</ci_upper_limit>
            <estimate_desc>Olo 5 mcg bid minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.135</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.024</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.087</ci_lower_limit>
            <ci_upper_limit>0.182</ci_upper_limit>
            <estimate_desc>Olo 10 mcg qd minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FVC Area Under Curve 0-24 Hours (AUC 0-24h) Response</title>
        <description>Response was defined as change from baseline. Study baseline FVC was defined as the mean of the available pre-dose FVC values at the randomisation visit. Means are adjusted for treatment, period, patient and study baseline. FVC AUC 0-24h was calculated using the trapezoidal rule, divided by the observation time to report in litres.</description>
        <time_frame>1 hour (h) prior and 10 minutes (min) prior to first dose (baseline) and -1 h, -10 mins, 30 min, 60 min, 2 h, 3 h, 4 h, 6 h, 8h, 10 h, 11 h 50 min, 12 h 30 min, 13 h, 14 h, 22 h, 23 h, and 23 h 50 min related to morning dose after 3 weeks</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo delivered by the Respimat Inhaler. Two actuations bid (morning and evening dosing).</description>
          </group>
          <group group_id="O2">
            <title>Olo 2.5 mcg Bid</title>
            <description>Olodaterol 2.5 mcg bid delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olo 5 mcg qd</title>
            <description>Olodaterol 5 mcg qd (morning) and matching Placebo in the evening delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O4">
            <title>Olo 5 mcg Bid</title>
            <description>Olodaterol 5 mcg bid delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O5">
            <title>Olo 10 mcg qd</title>
            <description>Olodaterol 10 mcg qd (morning) and matching Placebo in the evening delivered by the Respimat Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>FVC Area Under Curve 0-24 Hours (AUC 0-24h) Response</title>
          <description>Response was defined as change from baseline. Study baseline FVC was defined as the mean of the available pre-dose FVC values at the randomisation visit. Means are adjusted for treatment, period, patient and study baseline. FVC AUC 0-24h was calculated using the trapezoidal rule, divided by the observation time to report in litres.</description>
          <population>FAS</population>
          <units>Liter</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="200"/>
                <count group_id="O2" value="99"/>
                <count group_id="O3" value="99"/>
                <count group_id="O4" value="100"/>
                <count group_id="O5" value="101"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.029" spread="0.021"/>
                    <measurement group_id="O2" value="0.116" spread="0.026"/>
                    <measurement group_id="O3" value="0.099" spread="0.026"/>
                    <measurement group_id="O4" value="0.127" spread="0.026"/>
                    <measurement group_id="O5" value="0.111" spread="0.026"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.145</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.022</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.102</ci_lower_limit>
            <ci_upper_limit>0.188</ci_upper_limit>
            <estimate_desc>Olo 2.5 mcg bid minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.128</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.022</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.085</ci_lower_limit>
            <ci_upper_limit>0.171</ci_upper_limit>
            <estimate_desc>Olo 5 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.156</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.022</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.113</ci_lower_limit>
            <ci_upper_limit>0.198</ci_upper_limit>
            <estimate_desc>Olo 5 mcg bid minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.140</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.022</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.098</ci_lower_limit>
            <ci_upper_limit>0.182</ci_upper_limit>
            <estimate_desc>Olo 10 mcg qd minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Peak FVC Within 24 Hours Post-dose Response</title>
        <description>Response was defined as change from baseline. Study baseline FVC was defined as the mean of the available pre-dose FVC values at the randomisation visit. Peak FVC within 24 hours post-dose measured following the morning trial drug inhalation at the end of each 3 week period of randomised treatment. Means are adjusted for treatment, period, patient and study baseline.</description>
        <time_frame>1 hour (h) prior and 10 minutes (min) prior to first dose (baseline) and 30 min, 60 min, 2 h, 3 h, 4 h, 6 h, 8h, 10 h, 11 h 50 min, 12 h 30 min, 13 h, 14 h, 22 h, 23 h, and 23 h 50 min related to morning dose after 3 weeks</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo delivered by the Respimat Inhaler. Two actuations bid (morning and evening dosing).</description>
          </group>
          <group group_id="O2">
            <title>Olo 2.5 mcg Bid</title>
            <description>Olodaterol 2.5 mcg bid delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olo 5 mcg qd</title>
            <description>Olodaterol 5 mcg qd (morning) and matching Placebo in the evening delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O4">
            <title>Olo 5 mcg Bid</title>
            <description>Olodaterol 5 mcg bid delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O5">
            <title>Olo 10 mcg qd</title>
            <description>Olodaterol 10 mcg qd (morning) and matching Placebo in the evening delivered by the Respimat Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>Peak FVC Within 24 Hours Post-dose Response</title>
          <description>Response was defined as change from baseline. Study baseline FVC was defined as the mean of the available pre-dose FVC values at the randomisation visit. Peak FVC within 24 hours post-dose measured following the morning trial drug inhalation at the end of each 3 week period of randomised treatment. Means are adjusted for treatment, period, patient and study baseline.</description>
          <population>FAS</population>
          <units>Liter</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="201"/>
                <count group_id="O2" value="99"/>
                <count group_id="O3" value="99"/>
                <count group_id="O4" value="100"/>
                <count group_id="O5" value="101"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.246" spread="0.024"/>
                    <measurement group_id="O2" value="0.382" spread="0.030"/>
                    <measurement group_id="O3" value="0.371" spread="0.030"/>
                    <measurement group_id="O4" value="0.390" spread="0.030"/>
                    <measurement group_id="O5" value="0.373" spread="0.029"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.136</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.026</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.084</ci_lower_limit>
            <ci_upper_limit>0.187</ci_upper_limit>
            <estimate_desc>Olo 2.5 mcg bid minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.124</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.026</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.073</ci_lower_limit>
            <ci_upper_limit>0.176</ci_upper_limit>
            <estimate_desc>Olo 5 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.144</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.026</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.093</ci_lower_limit>
            <ci_upper_limit>0.195</ci_upper_limit>
            <estimate_desc>Olo 5 mcg bid minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.126</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.026</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.075</ci_lower_limit>
            <ci_upper_limit>0.177</ci_upper_limit>
            <estimate_desc>Olo 10 mcg qd minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Trough FVC Response</title>
        <description>Response was defined as change from baseline. Study baseline FVC was defined as the mean of the available pre-dose FVC values at the randomisation visit. Trough values were defined as the mean of 2 FVC values performed at 23 h and 23 h 50 min after the last morning trial drug inhalation at the end of each 3 week period of randomised treatment. Means are adjusted for treatment, period, patient and study baseline.</description>
        <time_frame>1 hour (h) prior and 10 minutes (min) prior to first dose (baseline) and 23 h, and 23 h 50 min related to morning dose after 3 weeks</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo delivered by the Respimat Inhaler. Two actuations bid (morning and evening dosing).</description>
          </group>
          <group group_id="O2">
            <title>Olo 2.5 mcg Bid</title>
            <description>Olodaterol 2.5 mcg bid delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olo 5 mcg qd</title>
            <description>Olodaterol 5 mcg qd (morning) and matching Placebo in the evening delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O4">
            <title>Olo 5 mcg Bid</title>
            <description>Olodaterol 5 mcg bid delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O5">
            <title>Olo 10 mcg qd</title>
            <description>Olodaterol 10 mcg qd (morning) and matching Placebo in the evening delivered by the Respimat Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>Trough FVC Response</title>
          <description>Response was defined as change from baseline. Study baseline FVC was defined as the mean of the available pre-dose FVC values at the randomisation visit. Trough values were defined as the mean of 2 FVC values performed at 23 h and 23 h 50 min after the last morning trial drug inhalation at the end of each 3 week period of randomised treatment. Means are adjusted for treatment, period, patient and study baseline.</description>
          <population>FAS</population>
          <units>Liter</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="201"/>
                <count group_id="O2" value="99"/>
                <count group_id="O3" value="99"/>
                <count group_id="O4" value="100"/>
                <count group_id="O5" value="101"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.013" spread="0.024"/>
                    <measurement group_id="O2" value="0.096" spread="0.031"/>
                    <measurement group_id="O3" value="0.079" spread="0.031"/>
                    <measurement group_id="O4" value="0.105" spread="0.031"/>
                    <measurement group_id="O5" value="0.098" spread="0.031"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.110</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.028</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.055</ci_lower_limit>
            <ci_upper_limit>0.165</ci_upper_limit>
            <estimate_desc>Olo 2.5 mcg bid minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0010</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.092</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.028</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.037</ci_lower_limit>
            <ci_upper_limit>0.147</ci_upper_limit>
            <estimate_desc>Olo 5 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.118</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.028</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.063</ci_lower_limit>
            <ci_upper_limit>0.172</ci_upper_limit>
            <estimate_desc>Olo 5 mcg bid minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.111</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.028</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.057</ci_lower_limit>
            <ci_upper_limit>0.166</ci_upper_limit>
            <estimate_desc>Olo 10 mcg qd minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Peak Expiratory Flow (PEF) Area Under Curve 0-12 Hours (AUC 0-12h) Response</title>
        <description>Response was defined as change from baseline. Study baseline PEF was defined as the mean of the available pre-dose PEF values at the randomisation visit. Means are adjusted for treatment, period, patient and study baseline. PEF AUC 0-12h was calculated using the trapezoidal rule, divided by the observation time to report in litres/seconds.</description>
        <time_frame>1 hour (h) prior and 10 minutes (min) prior to first dose (baseline) and -1 h, -10 mins, 30 min, 60 min, 2 h, 3 h, 4 h, 6 h, 8h, 10 h, 11 h 50 min related to morning dose after 3 weeks</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo delivered by the Respimat Inhaler. Two actuations bid (morning and evening dosing).</description>
          </group>
          <group group_id="O2">
            <title>Olo 2.5 mcg Bid</title>
            <description>Olodaterol 2.5 mcg bid delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olo 5 mcg qd</title>
            <description>Olodaterol 5 mcg qd (morning) and matching Placebo in the evening delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O4">
            <title>Olo 5 mcg Bid</title>
            <description>Olodaterol 5 mcg bid delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O5">
            <title>Olo 10 mcg qd</title>
            <description>Olodaterol 10 mcg qd (morning) and matching Placebo in the evening delivered by the Respimat Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>Peak Expiratory Flow (PEF) Area Under Curve 0-12 Hours (AUC 0-12h) Response</title>
          <description>Response was defined as change from baseline. Study baseline PEF was defined as the mean of the available pre-dose PEF values at the randomisation visit. Means are adjusted for treatment, period, patient and study baseline. PEF AUC 0-12h was calculated using the trapezoidal rule, divided by the observation time to report in litres/seconds.</description>
          <population>FAS</population>
          <units>Liter/sec</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="200"/>
                <count group_id="O2" value="99"/>
                <count group_id="O3" value="99"/>
                <count group_id="O4" value="100"/>
                <count group_id="O5" value="101"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.101" spread="0.060"/>
                    <measurement group_id="O2" value="0.730" spread="0.075"/>
                    <measurement group_id="O3" value="0.703" spread="0.075"/>
                    <measurement group_id="O4" value="0.732" spread="0.074"/>
                    <measurement group_id="O5" value="0.787" spread="0.074"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.629</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.065</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.500</ci_lower_limit>
            <ci_upper_limit>0.757</ci_upper_limit>
            <estimate_desc>Olo 2.5 mcg bid minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.601</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.065</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.473</ci_lower_limit>
            <ci_upper_limit>0.730</ci_upper_limit>
            <estimate_desc>Olo 5 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.631</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.065</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.503</ci_lower_limit>
            <ci_upper_limit>0.758</ci_upper_limit>
            <estimate_desc>Olo 5 mcg bid minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.685</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.065</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.558</ci_lower_limit>
            <ci_upper_limit>0.813</ci_upper_limit>
            <estimate_desc>Olo 10 mcg qd minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PEF Area Under Curve 12-24 Hours (AUC 12-24h) Response</title>
        <description>Response was defined as change from baseline. Study baseline PEF was defined as the mean of the available pre-dose PEF values at the randomisation visit. Means are adjusted for treatment, period, patient and study baseline. PEF AUC 12-24h was calculated using the trapezoidal rule, divided by the observation time to report in litres/seconds.</description>
        <time_frame>1 hour (h) prior and 10 minutes (min) prior to first dose (baseline) and 11 h 50 min, 12 h 30 min, 13 h, 14 h, 22 h, 23 h, and 23 h 50 min related to morning dose after 3 weeks</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo delivered by the Respimat Inhaler. Two actuations bid (morning and evening dosing).</description>
          </group>
          <group group_id="O2">
            <title>Olo 2.5 mcg Bid</title>
            <description>Olodaterol 2.5 mcg bid delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olo 5 mcg qd</title>
            <description>Olodaterol 5 mcg qd (morning) and matching Placebo in the evening delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O4">
            <title>Olo 5 mcg Bid</title>
            <description>Olodaterol 5 mcg bid delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O5">
            <title>Olo 10 mcg qd</title>
            <description>Olodaterol 10 mcg qd (morning) and matching Placebo in the evening delivered by the Respimat Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>PEF Area Under Curve 12-24 Hours (AUC 12-24h) Response</title>
          <description>Response was defined as change from baseline. Study baseline PEF was defined as the mean of the available pre-dose PEF values at the randomisation visit. Means are adjusted for treatment, period, patient and study baseline. PEF AUC 12-24h was calculated using the trapezoidal rule, divided by the observation time to report in litres/seconds.</description>
          <population>FAS</population>
          <units>Liter/sec</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="201"/>
                <count group_id="O2" value="99"/>
                <count group_id="O3" value="99"/>
                <count group_id="O4" value="100"/>
                <count group_id="O5" value="101"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.135" spread="0.061"/>
                    <measurement group_id="O2" value="0.530" spread="0.077"/>
                    <measurement group_id="O3" value="0.430" spread="0.076"/>
                    <measurement group_id="O4" value="0.567" spread="0.076"/>
                    <measurement group_id="O5" value="0.464" spread="0.076"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.665</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.068</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.532</ci_lower_limit>
            <ci_upper_limit>0.799</ci_upper_limit>
            <estimate_desc>Olo 2.5 mcg bid minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.564</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.068</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.431</ci_lower_limit>
            <ci_upper_limit>0.698</ci_upper_limit>
            <estimate_desc>Olo 5 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.702</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.068</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.569</ci_lower_limit>
            <ci_upper_limit>0.835</ci_upper_limit>
            <estimate_desc>Olo 5 mcg bid minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.599</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.067</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.467</ci_lower_limit>
            <ci_upper_limit>0.732</ci_upper_limit>
            <estimate_desc>Olo 10 mcg qd minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Peak Expiratory Flow (PEF) Area Under Curve 0-24 Hours (AUC 0-24h) Response</title>
        <description>Response was defined as change from baseline. Study baseline PEF was defined as the mean of the available pre-dose PEF values at the randomisation visit. Means are adjusted for treatment, period, patient and study baseline. PEF AUC 0-24h was calculated using the trapezoidal rule, divided by the observation time to report in litres/seconds.</description>
        <time_frame>1 hour (h) prior and 10 minutes (min) prior to first dose (baseline) and -1 h, -10 mins, 30 min, 60 min, 2 h, 3 h, 4 h, 6 h, 8h, 10 h, 11 h 50 min, 12 h 30 min, 13 h, 14 h, 22 h, 23 h, and 23 h 50 min related to morning dose after 3 weeks</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo delivered by the Respimat Inhaler. Two actuations bid (morning and evening dosing).</description>
          </group>
          <group group_id="O2">
            <title>Olo 2.5 mcg Bid</title>
            <description>Olodaterol 2.5 mcg bid delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olo 5 mcg qd</title>
            <description>Olodaterol 5 mcg qd (morning) and matching Placebo in the evening delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O4">
            <title>Olo 5 mcg Bid</title>
            <description>Olodaterol 5 mcg bid delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O5">
            <title>Olo 10 mcg qd</title>
            <description>Olodaterol 10 mcg qd (morning) and matching Placebo in the evening delivered by the Respimat Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>Peak Expiratory Flow (PEF) Area Under Curve 0-24 Hours (AUC 0-24h) Response</title>
          <description>Response was defined as change from baseline. Study baseline PEF was defined as the mean of the available pre-dose PEF values at the randomisation visit. Means are adjusted for treatment, period, patient and study baseline. PEF AUC 0-24h was calculated using the trapezoidal rule, divided by the observation time to report in litres/seconds.</description>
          <population>FAS</population>
          <units>Liter/sec</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="200"/>
                <count group_id="O2" value="99"/>
                <count group_id="O3" value="99"/>
                <count group_id="O4" value="100"/>
                <count group_id="O5" value="101"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.014" spread="0.059"/>
                    <measurement group_id="O2" value="0.627" spread="0.073"/>
                    <measurement group_id="O3" value="0.563" spread="0.073"/>
                    <measurement group_id="O4" value="0.653" spread="0.073"/>
                    <measurement group_id="O5" value="0.629" spread="0.073"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.641</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.063</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.516</ci_lower_limit>
            <ci_upper_limit>0.765</ci_upper_limit>
            <estimate_desc>Olo 2.5 mcg bid minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.577</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.063</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.453</ci_lower_limit>
            <ci_upper_limit>0.701</ci_upper_limit>
            <estimate_desc>Olo 5 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.667</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.063</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.544</ci_lower_limit>
            <ci_upper_limit>0.790</ci_upper_limit>
            <estimate_desc>Olo 5 mcg bid minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.643</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.063</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.519</ci_lower_limit>
            <ci_upper_limit>0.766</ci_upper_limit>
            <estimate_desc>Olo 10 mcg qd minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Peak PEF Within 24 Hours Post-dose Response</title>
        <description>Response was defined as change from baseline. Study baseline PEF was defined as the mean of the available pre-dose PEF values at the randomisation visit. Peak PEF within 24 hours post dose measured following the morning trial drug inhalation at the end of each 3 week period of randomised treatment. Means are adjusted for treatment, period, patient and study baseline.</description>
        <time_frame>1 hour (h) prior and 10 minutes (min) prior to first dose (baseline) and 30 min, 60 min, 2 h, 3 h, 4 h, 6 h, 8h, 10 h, 11 h 50 min, 12 h 30 min, 13 h, 14 h, 22 h, 23 h, and 23 h 50 min related to morning dose after 3 weeks</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo delivered by the Respimat Inhaler. Two actuations bid (morning and evening dosing).</description>
          </group>
          <group group_id="O2">
            <title>Olo 2.5 mcg Bid</title>
            <description>Olodaterol 2.5 mcg bid delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olo 5 mcg qd</title>
            <description>Olodaterol 5 mcg qd (morning) and matching Placebo in the evening delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O4">
            <title>Olo 5 mcg Bid</title>
            <description>Olodaterol 5 mcg bid delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O5">
            <title>Olo 10 mcg qd</title>
            <description>Olodaterol 10 mcg qd (morning) and matching Placebo in the evening delivered by the Respimat Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>Peak PEF Within 24 Hours Post-dose Response</title>
          <description>Response was defined as change from baseline. Study baseline PEF was defined as the mean of the available pre-dose PEF values at the randomisation visit. Peak PEF within 24 hours post dose measured following the morning trial drug inhalation at the end of each 3 week period of randomised treatment. Means are adjusted for treatment, period, patient and study baseline.</description>
          <population>FAS</population>
          <units>Liter/sec</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="201"/>
                <count group_id="O2" value="99"/>
                <count group_id="O3" value="99"/>
                <count group_id="O4" value="100"/>
                <count group_id="O5" value="101"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.663" spread="0.068"/>
                    <measurement group_id="O2" value="1.254" spread="0.087"/>
                    <measurement group_id="O3" value="1.185" spread="0.087"/>
                    <measurement group_id="O4" value="1.257" spread="0.086"/>
                    <measurement group_id="O5" value="1.286" spread="0.086"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.591</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.079</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.436</ci_lower_limit>
            <ci_upper_limit>0.746</ci_upper_limit>
            <estimate_desc>Olo 2.5 mcg bid minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.522</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.079</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.366</ci_lower_limit>
            <ci_upper_limit>0.677</ci_upper_limit>
            <estimate_desc>Olo 5 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.594</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.079</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.439</ci_lower_limit>
            <ci_upper_limit>0.749</ci_upper_limit>
            <estimate_desc>Olo 5 mcg bid minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.623</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.079</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.468</ci_lower_limit>
            <ci_upper_limit>0.777</ci_upper_limit>
            <estimate_desc>Olo 10 mcg qd minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Trough PEF Response</title>
        <description>Response was defined as change from baseline. Study baseline PEF was defined as the mean of the available pre-dose PEF values at the randomisation visit. Trough values were defined as the mean of 2 PEF values performed at 23 h and 23 h 50 min after the last morning trial drug inhalation at the end of each 3 week period of randomised treatment. Means are adjusted for treatment, period, patient and study baseline.</description>
        <time_frame>1 hour (h) prior and 10 minutes (min) prior to first dose (baseline) and 23 h, and 23 h 50 min related to morning dose after 3 weeks</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo delivered by the Respimat Inhaler. Two actuations bid (morning and evening dosing).</description>
          </group>
          <group group_id="O2">
            <title>Olo 2.5 mcg Bid</title>
            <description>Olodaterol 2.5 mcg bid delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olo 5 mcg qd</title>
            <description>Olodaterol 5 mcg qd (morning) and matching Placebo in the evening delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O4">
            <title>Olo 5 mcg Bid</title>
            <description>Olodaterol 5 mcg bid delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O5">
            <title>Olo 10 mcg qd</title>
            <description>Olodaterol 10 mcg qd (morning) and matching Placebo in the evening delivered by the Respimat Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>Trough PEF Response</title>
          <description>Response was defined as change from baseline. Study baseline PEF was defined as the mean of the available pre-dose PEF values at the randomisation visit. Trough values were defined as the mean of 2 PEF values performed at 23 h and 23 h 50 min after the last morning trial drug inhalation at the end of each 3 week period of randomised treatment. Means are adjusted for treatment, period, patient and study baseline.</description>
          <population>FAS</population>
          <units>Liter/sec</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="201"/>
                <count group_id="O2" value="99"/>
                <count group_id="O3" value="99"/>
                <count group_id="O4" value="100"/>
                <count group_id="O5" value="101"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.009" spread="0.062"/>
                    <measurement group_id="O2" value="0.520" spread="0.078"/>
                    <measurement group_id="O3" value="0.401" spread="0.078"/>
                    <measurement group_id="O4" value="0.594" spread="0.077"/>
                    <measurement group_id="O5" value="0.472" spread="0.077"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.529</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.068</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.396</ci_lower_limit>
            <ci_upper_limit>0.662</ci_upper_limit>
            <estimate_desc>Olo 2.5 mcg bid minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.410</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.068</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.277</ci_lower_limit>
            <ci_upper_limit>0.543</ci_upper_limit>
            <estimate_desc>Olo 5 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.603</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.067</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.471</ci_lower_limit>
            <ci_upper_limit>0.736</ci_upper_limit>
            <estimate_desc>Olo 5 mcg bid minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.481</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.067</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.349</ci_lower_limit>
            <ci_upper_limit>0.613</ci_upper_limit>
            <estimate_desc>Olo 10 mcg qd minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Pre-dose Morning PEF (PEF a.m.)</title>
        <description>PEF a.m. was measured by patients at home using the AM3 device (overall means obtained during each period of randomised treatment will be compared). Means are adjusted for treatment, period, patient and study baseline.</description>
        <time_frame>0-3 weeks</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo delivered by the Respimat Inhaler. Two actuations bid (morning and evening dosing).</description>
          </group>
          <group group_id="O2">
            <title>Olo 2.5 mcg Bid</title>
            <description>Olodaterol 2.5 mcg bid delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olo 5 mcg qd</title>
            <description>Olodaterol 5 mcg qd (morning) and matching Placebo in the evening delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O4">
            <title>Olo 5 mcg Bid</title>
            <description>Olodaterol 5 mcg bid delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O5">
            <title>Olo 10 mcg qd</title>
            <description>Olodaterol 10 mcg qd (morning) and matching Placebo in the evening delivered by the Respimat Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Pre-dose Morning PEF (PEF a.m.)</title>
          <description>PEF a.m. was measured by patients at home using the AM3 device (overall means obtained during each period of randomised treatment will be compared). Means are adjusted for treatment, period, patient and study baseline.</description>
          <population>FAS</population>
          <units>Liter/min</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="201"/>
                <count group_id="O2" value="99"/>
                <count group_id="O3" value="100"/>
                <count group_id="O4" value="101"/>
                <count group_id="O5" value="101"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="395.36" spread="2.857"/>
                    <measurement group_id="O2" value="428.32" spread="3.586"/>
                    <measurement group_id="O3" value="427.99" spread="3.575"/>
                    <measurement group_id="O4" value="427.02" spread="3.562"/>
                    <measurement group_id="O5" value="424.26" spread="3.562"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>32.957</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.180</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>26.709</ci_lower_limit>
            <ci_upper_limit>39.206</ci_upper_limit>
            <estimate_desc>Olo 2.5 mcg bid minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>32.632</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.167</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>26.409</ci_lower_limit>
            <ci_upper_limit>38.855</ci_upper_limit>
            <estimate_desc>Olo 5 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>31.660</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.161</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>25.448</ci_lower_limit>
            <ci_upper_limit>37.872</ci_upper_limit>
            <estimate_desc>Olo 5 mcg bid minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>28.895</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.161</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>22.683</ci_lower_limit>
            <ci_upper_limit>35.107</ci_upper_limit>
            <estimate_desc>Olo 10 mcg qd minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Pre-dose Evening PEF (PEF p.m.)</title>
        <description>PEF p.m. was measured by patients at home using the AM3 device (overall means obtained during each period of randomised treatment will be compared). Means are adjusted for treatment, period, patient and study baseline.</description>
        <time_frame>0-3 weeks</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo delivered by the Respimat Inhaler. Two actuations bid (morning and evening dosing).</description>
          </group>
          <group group_id="O2">
            <title>Olo 2.5 mcg Bid</title>
            <description>Olodaterol 2.5 mcg bid delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olo 5 mcg qd</title>
            <description>Olodaterol 5 mcg qd (morning) and matching Placebo in the evening delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O4">
            <title>Olo 5 mcg Bid</title>
            <description>Olodaterol 5 mcg bid delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O5">
            <title>Olo 10 mcg qd</title>
            <description>Olodaterol 10 mcg qd (morning) and matching Placebo in the evening delivered by the Respimat Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Pre-dose Evening PEF (PEF p.m.)</title>
          <description>PEF p.m. was measured by patients at home using the AM3 device (overall means obtained during each period of randomised treatment will be compared). Means are adjusted for treatment, period, patient and study baseline.</description>
          <population>FAS</population>
          <units>Liter/min</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="201"/>
                <count group_id="O2" value="99"/>
                <count group_id="O3" value="100"/>
                <count group_id="O4" value="101"/>
                <count group_id="O5" value="101"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="409.93" spread="2.717"/>
                    <measurement group_id="O2" value="438.80" spread="3.418"/>
                    <measurement group_id="O3" value="441.98" spread="3.407"/>
                    <measurement group_id="O4" value="441.74" spread="3.395"/>
                    <measurement group_id="O5" value="443.25" spread="3.395"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>28.870</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.046</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>22.884</ci_lower_limit>
            <ci_upper_limit>34.856</ci_upper_limit>
            <estimate_desc>Olo 2.5 mcg bid minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>32.056</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.034</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>26.094</ci_lower_limit>
            <ci_upper_limit>38.018</ci_upper_limit>
            <estimate_desc>Olo 5 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>31.816</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.028</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>25.864</ci_lower_limit>
            <ci_upper_limit>37.767</ci_upper_limit>
            <estimate_desc>Olo 5 mcg bid minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>33.327</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.028</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>27.375</ci_lower_limit>
            <ci_upper_limit>39.278</ci_upper_limit>
            <estimate_desc>Olo 10 mcg qd minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PEF Daily Variability</title>
        <description>PEF daily variability was assessed by patients at home using the AM3 device (overall means obtained during each period of randomised treatment will be compared). PEF daily variability is the absolute difference between the morning and the evening PEF value divided by the mean of these two values, expressed as a percent. Means are adjusted for treatment, period, patient and study baseline.</description>
        <time_frame>0-3 weeks</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo delivered by the Respimat Inhaler. Two actuations bid (morning and evening dosing).</description>
          </group>
          <group group_id="O2">
            <title>Olo 2.5 mcg Bid</title>
            <description>Olodaterol 2.5 mcg bid delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olo 5 mcg qd</title>
            <description>Olodaterol 5 mcg qd (morning) and matching Placebo in the evening delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O4">
            <title>Olo 5 mcg Bid</title>
            <description>Olodaterol 5 mcg bid delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O5">
            <title>Olo 10 mcg qd</title>
            <description>Olodaterol 10 mcg qd (morning) and matching Placebo in the evening delivered by the Respimat Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>PEF Daily Variability</title>
          <description>PEF daily variability was assessed by patients at home using the AM3 device (overall means obtained during each period of randomised treatment will be compared). PEF daily variability is the absolute difference between the morning and the evening PEF value divided by the mean of these two values, expressed as a percent. Means are adjusted for treatment, period, patient and study baseline.</description>
          <population>FAS</population>
          <units>Percentage</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="201"/>
                <count group_id="O2" value="99"/>
                <count group_id="O3" value="100"/>
                <count group_id="O4" value="101"/>
                <count group_id="O5" value="101"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.157" spread="0.288"/>
                    <measurement group_id="O2" value="8.576" spread="0.371"/>
                    <measurement group_id="O3" value="8.732" spread="0.369"/>
                    <measurement group_id="O4" value="8.419" spread="0.368"/>
                    <measurement group_id="O5" value="9.468" spread="0.368"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.581</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.346</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-2.262</ci_lower_limit>
            <ci_upper_limit>-0.900</ci_upper_limit>
            <estimate_desc>Olo 2.5 mcg bid minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.426</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.345</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-2.104</ci_lower_limit>
            <ci_upper_limit>-0.748</ci_upper_limit>
            <estimate_desc>Olo 5 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.738</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.344</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-2.415</ci_lower_limit>
            <ci_upper_limit>-1.062</ci_upper_limit>
            <estimate_desc>Olo 5 mcg bid minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0458</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.689</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.344</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.366</ci_lower_limit>
            <ci_upper_limit>-0.013</ci_upper_limit>
            <estimate_desc>Olo 10 mcg qd minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Pre-dose Morning FEV1 (FEV1 a.m.)</title>
        <description>FEV1 a.m. was measured by patients at home using the AM3 device (overall means obtained during each period of randomised treatment will be compared). Means are adjusted for treatment, period, patient and study baseline.</description>
        <time_frame>0-3 weeks</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo delivered by the Respimat Inhaler. Two actuations bid (morning and evening dosing).</description>
          </group>
          <group group_id="O2">
            <title>Olo 2.5 mcg Bid</title>
            <description>Olodaterol 2.5 mcg bid delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olo 5 mcg qd</title>
            <description>Olodaterol 5 mcg qd (morning) and matching Placebo in the evening delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O4">
            <title>Olo 5 mcg Bid</title>
            <description>Olodaterol 5 mcg bid delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O5">
            <title>Olo 10 mcg qd</title>
            <description>Olodaterol 10 mcg qd (morning) and matching Placebo in the evening delivered by the Respimat Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Pre-dose Morning FEV1 (FEV1 a.m.)</title>
          <description>FEV1 a.m. was measured by patients at home using the AM3 device (overall means obtained during each period of randomised treatment will be compared). Means are adjusted for treatment, period, patient and study baseline.</description>
          <population>FAS</population>
          <units>mL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="201"/>
                <count group_id="O2" value="99"/>
                <count group_id="O3" value="100"/>
                <count group_id="O4" value="101"/>
                <count group_id="O5" value="101"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2425.1" spread="17.870"/>
                    <measurement group_id="O2" value="2598.5" spread="22.276"/>
                    <measurement group_id="O3" value="2580.2" spread="22.208"/>
                    <measurement group_id="O4" value="2574.3" spread="22.133"/>
                    <measurement group_id="O5" value="2575.5" spread="22.133"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>173.391</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>19.484</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>135.099</ci_lower_limit>
            <ci_upper_limit>211.682</ci_upper_limit>
            <estimate_desc>Olo 2.5 mcg bid minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>155.097</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>19.406</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>116.961</ci_lower_limit>
            <ci_upper_limit>193.234</ci_upper_limit>
            <estimate_desc>Olo 5 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>149.268</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>19.369</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>111.204</ci_lower_limit>
            <ci_upper_limit>187.333</ci_upper_limit>
            <estimate_desc>Olo 5 mcg bid minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>150.441</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>19.369</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>112.377</ci_lower_limit>
            <ci_upper_limit>188.505</ci_upper_limit>
            <estimate_desc>Olo 10 mcg qd minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Pre-dose Evening FEV1 (FEV1 p.m.)</title>
        <description>FEV1 p.m. was measured by patients at home using the AM3 device (overall means obtained during each period of randomised treatment will be compared). Means are adjusted for treatment, period, patient and study baseline.</description>
        <time_frame>0-3 weeks</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo delivered by the Respimat Inhaler. Two actuations bid (morning and evening dosing).</description>
          </group>
          <group group_id="O2">
            <title>Olo 2.5 mcg Bid</title>
            <description>Olodaterol 2.5 mcg bid delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olo 5 mcg qd</title>
            <description>Olodaterol 5 mcg qd (morning) and matching Placebo in the evening delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O4">
            <title>Olo 5 mcg Bid</title>
            <description>Olodaterol 5 mcg bid delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O5">
            <title>Olo 10 mcg qd</title>
            <description>Olodaterol 10 mcg qd (morning) and matching Placebo in the evening delivered by the Respimat Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Pre-dose Evening FEV1 (FEV1 p.m.)</title>
          <description>FEV1 p.m. was measured by patients at home using the AM3 device (overall means obtained during each period of randomised treatment will be compared). Means are adjusted for treatment, period, patient and study baseline.</description>
          <population>FAS</population>
          <units>mL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="201"/>
                <count group_id="O2" value="99"/>
                <count group_id="O3" value="100"/>
                <count group_id="O4" value="101"/>
                <count group_id="O5" value="101"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2474.3" spread="17.692"/>
                    <measurement group_id="O2" value="2616.6" spread="21.949"/>
                    <measurement group_id="O3" value="2606.5" spread="21.884"/>
                    <measurement group_id="O4" value="2616.5" spread="21.810"/>
                    <measurement group_id="O5" value="2631.7" spread="21.809"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>142.251</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>18.997</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>104.916</ci_lower_limit>
            <ci_upper_limit>179.586</ci_upper_limit>
            <estimate_desc>Olo 2.5 mcg bid minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>132.138</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>18.920</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>94.954</ci_lower_limit>
            <ci_upper_limit>169.322</ci_upper_limit>
            <estimate_desc>Olo 5 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>142.136</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>18.885</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>105.021</ci_lower_limit>
            <ci_upper_limit>179.251</ci_upper_limit>
            <estimate_desc>Olo 5 mcg bid minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>157.306</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>18.885</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>120.192</ci_lower_limit>
            <ci_upper_limit>194.420</ci_upper_limit>
            <estimate_desc>Olo 10 mcg qd minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Number of Puffs of Rescue Medication During the Whole Day</title>
        <description>Mean of daily use of salbutamol (albuterol) rescue medication as needed during the entire study period. Assessed by patients at home using the AM3 device (overall mean number obtained during each period of randomised treatment will be compared). Means are adjusted for treatment, period, patient and study baseline.</description>
        <time_frame>0-3 weeks</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo delivered by the Respimat Inhaler. Two actuations bid (morning and evening dosing).</description>
          </group>
          <group group_id="O2">
            <title>Olo 2.5 mcg Bid</title>
            <description>Olodaterol 2.5 mcg bid delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olo 5 mcg qd</title>
            <description>Olodaterol 5 mcg qd (morning) and matching Placebo in the evening delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O4">
            <title>Olo 5 mcg Bid</title>
            <description>Olodaterol 5 mcg bid delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O5">
            <title>Olo 10 mcg qd</title>
            <description>Olodaterol 10 mcg qd (morning) and matching Placebo in the evening delivered by the Respimat Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Number of Puffs of Rescue Medication During the Whole Day</title>
          <description>Mean of daily use of salbutamol (albuterol) rescue medication as needed during the entire study period. Assessed by patients at home using the AM3 device (overall mean number obtained during each period of randomised treatment will be compared). Means are adjusted for treatment, period, patient and study baseline.</description>
          <population>FAS</population>
          <units>Puffs</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="201"/>
                <count group_id="O2" value="99"/>
                <count group_id="O3" value="100"/>
                <count group_id="O4" value="101"/>
                <count group_id="O5" value="101"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.665" spread="0.091"/>
                    <measurement group_id="O2" value="1.110" spread="0.120"/>
                    <measurement group_id="O3" value="1.028" spread="0.119"/>
                    <measurement group_id="O4" value="1.077" spread="0.119"/>
                    <measurement group_id="O5" value="1.119" spread="0.119"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.554</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.115</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.780</ci_lower_limit>
            <ci_upper_limit>-0.329</ci_upper_limit>
            <estimate_desc>Olo 2.5 mcg bid minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.637</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.114</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.862</ci_lower_limit>
            <ci_upper_limit>-0.412</ci_upper_limit>
            <estimate_desc>Olo 5 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.588</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.114</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.813</ci_lower_limit>
            <ci_upper_limit>-0.364</ci_upper_limit>
            <estimate_desc>Olo 5 mcg bid minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.546</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.114</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.770</ci_lower_limit>
            <ci_upper_limit>-0.322</ci_upper_limit>
            <estimate_desc>Olo 10 mcg qd minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Asthma Symptom Free Days</title>
        <description>Percentage of asthma-symptom free days of each treatment period was calculated as the number of symptom-free days divided by the number of days on treatment multiplied by 100. A symptom-free day was defined as a day in which no asthma symptoms were recorded, no rescue medication was recorded, activities during the day were not at all limited due to asthma, no shortness of breath during the day was recorded, no wheezing or coughing during the day and no night-time awakenings due to asthma were recorded. Assessed by patients at home using the AM3 device.</description>
        <time_frame>0-3 weeks</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo delivered by the Respimat Inhaler. Two actuations bid (morning and evening dosing).</description>
          </group>
          <group group_id="O2">
            <title>Olo 2.5 mcg Bid</title>
            <description>Olodaterol 2.5 mcg bid delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olo 5 mcg qd</title>
            <description>Olodaterol 5 mcg qd (morning) and matching Placebo in the evening delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O4">
            <title>Olo 5 mcg Bid</title>
            <description>Olodaterol 5 mcg bid delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O5">
            <title>Olo 10 mcg qd</title>
            <description>Olodaterol 10 mcg qd (morning) and matching Placebo in the evening delivered by the Respimat Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Asthma Symptom Free Days</title>
          <description>Percentage of asthma-symptom free days of each treatment period was calculated as the number of symptom-free days divided by the number of days on treatment multiplied by 100. A symptom-free day was defined as a day in which no asthma symptoms were recorded, no rescue medication was recorded, activities during the day were not at all limited due to asthma, no shortness of breath during the day was recorded, no wheezing or coughing during the day and no night-time awakenings due to asthma were recorded. Assessed by patients at home using the AM3 device.</description>
          <population>FAS</population>
          <units>Percentage of asthma symptom free days</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="201"/>
                <count group_id="O2" value="99"/>
                <count group_id="O3" value="100"/>
                <count group_id="O4" value="101"/>
                <count group_id="O5" value="101"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.630" spread="2.235"/>
                    <measurement group_id="O2" value="33.929" spread="3.554"/>
                    <measurement group_id="O3" value="36.306" spread="3.644"/>
                    <measurement group_id="O4" value="28.844" spread="3.271"/>
                    <measurement group_id="O5" value="28.049" spread="3.368"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients Categorized by Highest Number of Night Time Awakenings (Overall)</title>
        <description>Assessed by patients at home using the AM3 device during each period of randomised treatment.</description>
        <time_frame>0-3 weeks</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo delivered by the Respimat Inhaler. Two actuations bid (morning and evening dosing).</description>
          </group>
          <group group_id="O2">
            <title>Olo 2.5 mcg Bid</title>
            <description>Olodaterol 2.5 mcg bid delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olo 5 mcg qd</title>
            <description>Olodaterol 5 mcg qd (morning) and matching Placebo in the evening delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O4">
            <title>Olo 5 mcg Bid</title>
            <description>Olodaterol 5 mcg bid delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O5">
            <title>Olo 10 mcg qd</title>
            <description>Olodaterol 10 mcg qd (morning) and matching Placebo in the evening delivered by the Respimat Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Categorized by Highest Number of Night Time Awakenings (Overall)</title>
          <description>Assessed by patients at home using the AM3 device during each period of randomised treatment.</description>
          <population>FAS</population>
          <units>Number of patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="201"/>
                <count group_id="O2" value="99"/>
                <count group_id="O3" value="100"/>
                <count group_id="O4" value="101"/>
                <count group_id="O5" value="101"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Did not wake up</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93"/>
                    <measurement group_id="O2" value="50"/>
                    <measurement group_id="O3" value="53"/>
                    <measurement group_id="O4" value="44"/>
                    <measurement group_id="O5" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Woke up once</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67"/>
                    <measurement group_id="O2" value="31"/>
                    <measurement group_id="O3" value="36"/>
                    <measurement group_id="O4" value="41"/>
                    <measurement group_id="O5" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Woke up 2-5 times</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36"/>
                    <measurement group_id="O2" value="18"/>
                    <measurement group_id="O3" value="10"/>
                    <measurement group_id="O4" value="14"/>
                    <measurement group_id="O5" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Woke up &gt; 5 times</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Was awake all night</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients Categorized by Worst Asthma Daytime Symptoms (Overall)</title>
        <description>Assessed by patients at home using the AM3 device during each period of randomised treatment .</description>
        <time_frame>0-3 weeks</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo delivered by the Respimat Inhaler. Two actuations bid (morning and evening dosing).</description>
          </group>
          <group group_id="O2">
            <title>Olo 2.5 mcg Bid</title>
            <description>Olodaterol 2.5 mcg bid delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olo 5 mcg qd</title>
            <description>Olodaterol 5 mcg qd (morning) and matching Placebo in the evening delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O4">
            <title>Olo 5 mcg Bid</title>
            <description>Olodaterol 5 mcg bid delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O5">
            <title>Olo 10 mcg qd</title>
            <description>Olodaterol 10 mcg qd (morning) and matching Placebo in the evening delivered by the Respimat Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Categorized by Worst Asthma Daytime Symptoms (Overall)</title>
          <description>Assessed by patients at home using the AM3 device during each period of randomised treatment .</description>
          <population>FAS</population>
          <units>Number of patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="201"/>
                <count group_id="O2" value="99"/>
                <count group_id="O3" value="100"/>
                <count group_id="O4" value="101"/>
                <count group_id="O5" value="101"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>No asthma symptoms</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                    <measurement group_id="O2" value="24"/>
                    <measurement group_id="O3" value="27"/>
                    <measurement group_id="O4" value="18"/>
                    <measurement group_id="O5" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mild asthma symptoms</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66"/>
                    <measurement group_id="O2" value="45"/>
                    <measurement group_id="O3" value="42"/>
                    <measurement group_id="O4" value="42"/>
                    <measurement group_id="O5" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate asthma symptoms</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85"/>
                    <measurement group_id="O2" value="25"/>
                    <measurement group_id="O3" value="27"/>
                    <measurement group_id="O4" value="36"/>
                    <measurement group_id="O5" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe asthma symptoms</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Very severe asthma symptoms</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients Categorized by Worst Asthma Nighttime Symptoms (Overall)</title>
        <description>Assessed by patients at home using the AM3 device during each period of randomised treatment.</description>
        <time_frame>0-3 weeks</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo delivered by the Respimat Inhaler. Two actuations bid (morning and evening dosing).</description>
          </group>
          <group group_id="O2">
            <title>Olo 2.5 mcg Bid</title>
            <description>Olodaterol 2.5 mcg bid delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olo 5 mcg qd</title>
            <description>Olodaterol 5 mcg qd (morning) and matching Placebo in the evening delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O4">
            <title>Olo 5 mcg Bid</title>
            <description>Olodaterol 5 mcg bid delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O5">
            <title>Olo 10 mcg qd</title>
            <description>Olodaterol 10 mcg qd (morning) and matching Placebo in the evening delivered by the Respimat Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Categorized by Worst Asthma Nighttime Symptoms (Overall)</title>
          <description>Assessed by patients at home using the AM3 device during each period of randomised treatment.</description>
          <population>FAS</population>
          <units>Number of patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="201"/>
                <count group_id="O2" value="99"/>
                <count group_id="O3" value="100"/>
                <count group_id="O4" value="101"/>
                <count group_id="O5" value="101"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>No asthma symptoms</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39"/>
                    <measurement group_id="O2" value="32"/>
                    <measurement group_id="O3" value="29"/>
                    <measurement group_id="O4" value="21"/>
                    <measurement group_id="O5" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mild asthma symptoms</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76"/>
                    <measurement group_id="O2" value="35"/>
                    <measurement group_id="O3" value="38"/>
                    <measurement group_id="O4" value="48"/>
                    <measurement group_id="O5" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate asthma symptoms</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74"/>
                    <measurement group_id="O2" value="26"/>
                    <measurement group_id="O3" value="32"/>
                    <measurement group_id="O4" value="29"/>
                    <measurement group_id="O5" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe asthma symptoms</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Very severe asthma symptoms</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Asthma Control Questionnaire (ACQ) Score</title>
        <description>Control of asthma as assessed by the ACQ at the end of each 3-week treatment period.The ACQ contains 7 questions, each question has a 7 point scale from 0 (no symptoms) till 6 (highest intensity). Total score was defined as the sum of all items divided by the number of items.</description>
        <time_frame>3 weeks</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo delivered by the Respimat Inhaler. Two actuations bid (morning and evening dosing).</description>
          </group>
          <group group_id="O2">
            <title>Olo 2.5 mcg Bid</title>
            <description>Olodaterol 2.5 mcg bid delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olo 5 mcg qd</title>
            <description>Olodaterol 5 mcg qd (morning) and matching Placebo in the evening delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O4">
            <title>Olo 5 mcg Bid</title>
            <description>Olodaterol 5 mcg bid delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O5">
            <title>Olo 10 mcg qd</title>
            <description>Olodaterol 10 mcg qd (morning) and matching Placebo in the evening delivered by the Respimat Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>Total Asthma Control Questionnaire (ACQ) Score</title>
          <description>Control of asthma as assessed by the ACQ at the end of each 3-week treatment period.The ACQ contains 7 questions, each question has a 7 point scale from 0 (no symptoms) till 6 (highest intensity). Total score was defined as the sum of all items divided by the number of items.</description>
          <population>FAS</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="201"/>
                <count group_id="O2" value="99"/>
                <count group_id="O3" value="100"/>
                <count group_id="O4" value="101"/>
                <count group_id="O5" value="101"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.613" spread="0.040"/>
                    <measurement group_id="O2" value="1.256" spread="0.053"/>
                    <measurement group_id="O3" value="1.317" spread="0.053"/>
                    <measurement group_id="O4" value="1.312" spread="0.053"/>
                    <measurement group_id="O5" value="1.311" spread="0.053"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.357</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.053</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.461</ci_lower_limit>
            <ci_upper_limit>-0.253</ci_upper_limit>
            <estimate_desc>Olo 2.5 mcg bid minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.296</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.053</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.400</ci_lower_limit>
            <ci_upper_limit>-0.192</ci_upper_limit>
            <estimate_desc>Olo 5 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.301</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.053</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.405</ci_lower_limit>
            <ci_upper_limit>-0.198</ci_upper_limit>
            <estimate_desc>Olo 5 mcg bid minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.302</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.053</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.405</ci_lower_limit>
            <ci_upper_limit>-0.198</ci_upper_limit>
            <estimate_desc>Olo 10 mcg qd minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Relevant Abnormalities for Vital Signs, Blood Chemistry, Haematology, Urinalysis and ECG</title>
        <description>Clinical relevant abnormalities for Vital Signs, Blood Chemistry, Haematology, Urinalysis and ECG. New abnormal findings or worsening of baseline conditions were reported as Adverse Events. Time frame for adverse event reporting includes 12 days into the subsequent washout or post-treatment period.</description>
        <time_frame>3 weeks + 12 days</time_frame>
        <population>Treated set</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo delivered by the Respimat Inhaler. Two actuations bid (morning and evening dosing).</description>
          </group>
          <group group_id="O2">
            <title>Olo 2.5 mcg Bid</title>
            <description>Olodaterol 2.5 mcg bid delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olo 5 mcg qd</title>
            <description>Olodaterol 5 mcg qd (morning) and matching Placebo in the evening delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O4">
            <title>Olo 5 mcg Bid</title>
            <description>Olodaterol 5 mcg bid delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O5">
            <title>Olo 10 mcg qd</title>
            <description>Olodaterol 10 mcg qd (morning) and matching Placebo in the evening delivered by the Respimat Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Relevant Abnormalities for Vital Signs, Blood Chemistry, Haematology, Urinalysis and ECG</title>
          <description>Clinical relevant abnormalities for Vital Signs, Blood Chemistry, Haematology, Urinalysis and ECG. New abnormal findings or worsening of baseline conditions were reported as Adverse Events. Time frame for adverse event reporting includes 12 days into the subsequent washout or post-treatment period.</description>
          <population>Treated set</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="201"/>
                <count group_id="O2" value="101"/>
                <count group_id="O3" value="101"/>
                <count group_id="O4" value="101"/>
                <count group_id="O5" value="102"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Atrioventricular block first degree</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sinus tachycardia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Aspartate aminotransferase increased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Blood creatinine increased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Blood glucose increased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Blood urea abnormal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gamma-glutamyltransferase increased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Blood creatine phosphokinase increased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Blood urine present</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anaemia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hypertension</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>3 weeks treatment period + 12 days</time_frame>
      <desc>Time frame for adverse event reporting includes 12 days into the subsequent washout or post-treatment period.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Matching Placebo delivered by the Respimat Inhaler. Two actuations bid (morning and evening dosing).</description>
        </group>
        <group group_id="E2">
          <title>Olo 2.5 mcg Bid</title>
          <description>Olodaterol 2.5 mcg bid delivered by the Respimat Inhaler.</description>
        </group>
        <group group_id="E3">
          <title>Olo 5 mcg qd</title>
          <description>Olodaterol 5 mcg qd (morning) and matching Placebo in the evening delivered by the Respimat Inhaler.</description>
        </group>
        <group group_id="E4">
          <title>Olo 5 mcg Bid</title>
          <description>Olodaterol 5 mcg bid delivered by the Respimat Inhaler.</description>
        </group>
        <group group_id="E5">
          <title>Olo 10 mcg qd</title>
          <description>Olodaterol 10 mcg qd (morning) and matching Placebo in the evening delivered by the Respimat Inhaler.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 14.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="201"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="101"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="101"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="101"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="201"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="101"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="101"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Laceration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="101"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Meniscus lesion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="201"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Boehringer Ingelheim Call Center</name_or_title>
      <organization>Boehringer Ingelheim Pharmaceuticals</organization>
      <phone>1-800-243-0127</phone>
      <email>clintriage.rdg@boehringer-ingelheim.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

